Company reportsPresentationsAnnouncementsCurrently selectedAnnual General MeetingFinancial calendarCorporate governanceData of sharesConferences, roadshowsAnalystsContact Announcements Change in the Board of Directors of Gedeon Richter Plc.09/02/19Composition of share capital and voting rights08/30/19Extraordinary Announcement08/21/19Richter launched Terrosa®, its biosimilar teriparatide across Europe08/20/19Gedeon Richter Plc. ("Richter") today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly's Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Mitsubishi received regulatory approval for Cariprazine in part of ASEAN (Singapore and Thailand)08/08/19Gedeon Richter Plc (“Richter”) today announced that Mitsubishi Tanabe Pharma Corporation’s (“MTPC”) subsidiaries in ASEAN obtained the regulatory approval of cariprazine for the treatment of schizophrenia. Current approvals have been granted in Singapore and in Thailand. Archive
Richter launched Terrosa®, its biosimilar teriparatide across Europe08/20/19Gedeon Richter Plc. ("Richter") today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly's Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.
Mitsubishi received regulatory approval for Cariprazine in part of ASEAN (Singapore and Thailand)08/08/19Gedeon Richter Plc (“Richter”) today announced that Mitsubishi Tanabe Pharma Corporation’s (“MTPC”) subsidiaries in ASEAN obtained the regulatory approval of cariprazine for the treatment of schizophrenia. Current approvals have been granted in Singapore and in Thailand.
